65,437 trials
Prostate Cancer
Primary: Percentage of Participants With Effective Castration Rate Over 24 Weeks — 91; 91; 96 percentage of participants
Hodgkin's Disease
Primary: Transplant Related Mortality Rate — 1; 6 Participants
Gastroesophageal Reflux
Primary: Count of Patients Agreeing to Volunteer for the Study — 28 Participants
Coronary Artery Disease
Primary: Ticagrelor Pharmacokinetics — 3301; 2107 ng*hr/mL
Heart Failure
Primary: Number of Patients Free From LV Lead-related Complications Through 3 Months — 4 Participants — p=0.05
Vulvar Cancer
Primary: Percentage of Participants With Clinical and Histologic Remission — 75 % of participants
Pleural Effusion
Primary: Feasibility of Using Indwelling Tunneled Pleural Catheters for the Management of Hepatic Hydrothorax — 25 Participants
Breast Cancer · Advanced Malignant Solid Tumors
Primary: Overall Response Rate — 35.9; 13.3 percentage of participants
Esophageal Cancer · Gastric Cancer
Primary: 6-month Progression-free Survival (PFS) — 60.5; 57.1 percent probability — p=0.72
Osteoporosis
Primary: Change in Spine Bone Density From Baseline to 2 Years — 8.3; 9.5; 12.9 percent change
Schizophrenia · Schizoaffective Disorder
Primary: PANSS Total Score — 58.2; 53.5 units on a scale
Cocaine-Related Disorders
Primary: Urine Toxicology for Cocaine — 3; 8; 3 Participants
Metastatic Pancreatic Cancer
Primary: Overall Survival (OS) in Subjects Receiving Test Treatments (FAS) — 6.28; 4.07 months
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c — -1.51; -1.78; -1.11; -1.37 percentage of HbA1c — p=<0.0001
Multiple Myeloma
Primary: Dose Limiting Toxicities (DLT) - Number of Participants With at Least 1 DLT — 0; 0; 0; 0 Participants